Help us raise awareness about the inequities in glioblastoma treatment across the USA.



Glioblastoma Bill of Rights graphics
Right click to download



Right click to download
Erika was thriving as a GBM survivor until it came back. She’s finding out that the options for recurrent GBM are few.
Remembering Adam Hayden, a giant in the glioblastoma community (1982-2025)
In 2025 we met with people living with GBM and their care partners, traveled to conferences, and began to tell the world about our GBM Disparities Survey.
“It was incredibly energizing to see how OBB’s work is not only documenting problems but also driving conversations and initiatives that could improve access to care and quality of life for GBM patients across diverse communities.” Jacob Ellen writes about his experience with the SNO 2025 conference where OurBrainBank presented two posters and won an award.
OurBrainBank 2025 press release about disparities in GBM treatment across the USA. Survey of 500+ patients and care partners show inequities — many Americans are not offered their best chance via a clinical trial, second opinion, and other factors.
Erika was thriving as a GBM survivor until it came back. She’s finding out that the options for recurrent GBM are few.
Remembering Adam Hayden, a giant in the glioblastoma community (1982-2025)
In 2025 we met with people living with GBM and their care partners, traveled to conferences, and began to tell the world about our GBM Disparities Survey.
“It was incredibly energizing to see how OBB’s work is not only documenting problems but also driving conversations and initiatives that could improve access to care and quality of life for GBM patients across diverse communities.” Jacob Ellen writes about his experience with the SNO 2025 conference where OurBrainBank presented two posters and won an award.
OurBrainBank 2025 press release about disparities in GBM treatment across the USA. Survey of 500+ patients and care partners show inequities — many Americans are not offered their best chance via a clinical trial, second opinion, and other factors.